Calcium ion-binding genes can predict tumor mutation burden and immune checkpoint blockade response in a pan-cancer model.

ABSTRACT:

Background

Tumor mutation burden (TMB), the total number of nonsynonymous mutations in the tumor genome, is a well-established biomarker for predicting responses to immune checkpoint blockade (ICB) therapy across various cancers. Patients with high TMB tend to exhibit better responses to ICB. Recently, targeted gene panels have been developed to estimate TMB before treatment. These panels are enriched for calcium ion-binding genes. However, a direct link between TMB and calcium ion-binding genes has not been reported in the literature to date.

Methods

The association between TMB and calcium ion-binding genes was analyzed using mutation data from The Cancer Genome Atlas (TCGA) database. In addition, a pan-cancer model was constructed to estimate TMB based solely on calcium io

SUBMITTER: Lin WY 

PROVIDER: S-EPMC12267738 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature